Patents by Inventor Kala Visvanathan

Kala Visvanathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genome-wide methylation analysis and use to identify genes specific to breast cancer hormone receptor status and risk of recurrence
    Patent number: 10316361
    Abstract: To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: June 11, 2019
    Assignee: THE JOHN HOPKINS UNIVERSITY
    Inventors: Saraswati V. Sukumar, Christopher Benedict Umbricht, Antonio C. Wolff, Mary Jo Steele Fackler, Zhe Zhang, Leslie M. Cope, Kala Visvanathan, Peng Huang
  • GENOME-WIDE METHYLATION ANALYSIS AND USE TO IDENTIFY GENES SPECIFIC TO BREAST CANCER HORMONE RECEPTOR STATUS AND RISK OF RECURRANCE
    Publication number: 20140221242
    Abstract: To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.
    Type: Application
    Filed: July 16, 2012
    Publication date: August 7, 2014
    Applicant: THE JOHN HOPKINS UNIVERSITY
    Inventors: Saraswati V. Sukumar, Christopher Benedict Umbricht, Antonio C. Wolff, Mary Jo Steele Fackler, Zhe Zhang, Leslie M. Cope, Kala Visvanathan, Peng Huang